{"id":"NCT04102501","sponsor":"Biojiva LLC","briefTitle":"A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia","officialTitle":"A Randomized, Double-Blind, Controlled, Phase 2/3 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-30","primaryCompletion":"2021-08-23","completion":"2021-08-23","firstPosted":"2019-09-25","resultsPosted":"2022-05-27","lastUpdate":"2022-05-27"},"enrollment":65,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Friedreich's Ataxia"],"interventions":[{"type":"DRUG","name":"RT001","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"RT001","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the Efficacy, Long Term Safety and Tolerability of RT001 in subjects with Friedreich's Ataxia","primaryOutcome":{"measure":"Change From Baseline to 11 Months in Maximum Consumption of Oxygen (mlO2/kg/Min) Using Cardiopulmonary Exercise Testing (CPET)","timeFrame":"11 months","effectByArm":[{"arm":"RT001","deltaMin":0.05,"sd":0.04},{"arm":"Placebo","deltaMin":0.08,"sd":0.04}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5858"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":33},"commonTop":["Falls","nausea","diarrhea","headache"]}}